Virtually every country in the world has responded to the corona shock with fiscal policy. But even within EM world there are HUGE differences in the capacity & willingness to respond btw, for instance, India/Mexico and Malaysia/Brazil/Chile.https://t.co/bMW7vfHiT8pic.twitter.com/yzY3u95ge5
Will SARS-CoV-2 become endemic? Science. From the Body: “Although reinfections can occur, the number of reinfection cases is not currently sufficient to generalize the duration of immunity at population scales or the severity of repeat infection. Whether reinfections will be commonplace, how often they will occur, how contagious reinfected individuals will be, and whether the risk of severe clinical outcomes changes with subsequent infection remain to be understood.”
Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations NEJM. From the Body: “Recognizing the gravity of the current public health emergency and the importance of making a vaccine available as soon as possible, we believe that a median 2-month follow-up after completion of the vaccine regimen will provide the necessary safety and effectiveness data to support distribution of an investigational vaccine under an EUA. Curtailment of this minimum follow-up could destroy the scientific credibility of the decision to authorize any vaccine for use under an EUA in the United States.”
Postlicensure Evaluation of COVID-19 Vaccines JAMA. From the Abstract: “The widespread morbidity, mortality, and societal ramifications of the COVID-19 pandemic have motivated the testing and development of vaccines at an unprecedented pace, with possible introduction in the population in the near future. More than 200 SARS-CoV-2 vaccines using multiple (some novel) platforms are being developed, and several candidates have entered phase 3 clinical trials. Vaccines are likely to be licensed as soon as safety and efficacy can be demonstrated. However, many unanswered questions will need postlicensure assessment, including the magnitude of protection across population subgroups defined by age, underlying conditions, and race/ethnicity; the duration of protection; comparative evaluations of vaccine types; assessments of 1 vs 2 doses of vaccination; and a more comprehensive understanding of safety, including rare complications.”
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals American Society of Microbiology. From the Importance section: “While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.”
How the coronavirus’s genetic code can help control outbreaks WaPo. This sentence caught my eye: “While U.K. scientists, backed by their government, began work early to create a centralized tracking system that could benefit researchers around the country, the U.S. effort has remained more diffuse and disorganized.” Could that be — hear me out — because the U.K. has a national health service? (Hilariously, neither “National Health Service” nor “NHS” appear in the article.) This from a story that begins with a cute graphic that invites you to imagine “Scienceville”!
Three weeks before Election Day, Trump allies go after Hunter — and Joe — Biden WaPo (LR). “The report Wednesday did not markedly advance what is already known about Hunter Biden’s foreign business dealings, other than to suggest that at one point he gave Vadym Pozharskyi, a Ukrainian business colleague, ‘an opportunity’ to meet his father. The Biden campaign said the vice president’s schedule indicated no such meeting.” So that’s alright then:
I asked Joe Biden: What is your response to the NYPost story about your son, sir?
He called it a “smear campaign” and then went after me. “I know you’d ask it. I have no response, it’s another smear campaign, right up your alley, those are the questions you always ask.” pic.twitter.com/Eo6VD4TqxD